Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral glucose-lowering agents. Apart from their glucose-lowering effects, large clinical trials assessing certain SGLT2 inhibitors have revealed cardiac and renal protective effects in non-diabetic patients. These excellent outcomes...
Main Authors: | Kai-Fan Tsai, Yung-Lung Chen, Terry Ting-Yu Chiou, Tian-Huei Chu, Lung-Chih Li, Hwee-Yeong Ng, Wen-Chin Lee, Chien-Te Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Antioxidants |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3921/10/8/1166 |
Similar Items
-
SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
by: Daiji Kawanami, et al.
Published: (2017-05-01) -
Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
by: Yi-Chou Hou, et al.
Published: (2020-10-01) -
SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
by: Guntram Schernthaner, et al.
Published: (2019-06-01) -
Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations
by: Jasna Klen, et al.
Published: (2021-09-01) -
Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice
by: Masa-Ki Inoue, et al.
Published: (2019-07-01)